Oncology Launch Study Probes How to Leverage Cost Savings from Initial Launch to Second Indication Launch

CHAPEL HILL, N.C., Jan. 26, 2018 /PRNewswire/ -- Pharmaceutical companies that have launched a new oncology product often pursue a second indication for the same product. The prevalent thinking across the industry is that a company can leverage cost savings for the second launch by utilizing some of the infrastructure and staff from the first launch.

However, it can be difficult to ascertain which activities and staffing areas provide the best savings while not jeopardizing the launch success of a second indication. Research and consulting leader Best Practices, LLC undertook a primary research project to provide oncology leaders with answers to this dilemma.

According to the new study, oncology franchises report various cost savings by leveraging existing infrastructure to save a high percentage of second-indication launch resources, particularly in the areas of patient services, non-personal promotion and direct to consumer expenses.  The cost-cutting effect of leveraging existing infrastructure is greatest when second indication is in the same or closely related therapeutic areas.

The study provides insights across a number of other key areas of managing an oncology launch, including current staffing and investment benchmarks for launch-related activities and functions for new oncology products. This study will help marketing and brand leaders identify staffing and investment priorities across pre-launch, launch and post-launch activities for oncology products.

The new study, "What it Takes to Successfully Launch an Oncology Product in the U.S. Marketplace," will inform oncology launch teams with evidence-based benchmarks around investment, staffing and timing requirements needed to successfully launch new oncology drugs in the U.S. market.

For this study, Best Practices, LLC probed oncology product investment levels for 12 companies and 20 U.S. project launches.

Some of the topics addressed in the 148-page study include:

• Total Investment & Staffing Benchmarks Segmented by Peak Year Sales Forecast
• Staffing and Investment Benchmark Analysis for Launch Activities
• Franchise Leverage or Synergy
• U.S. Oncology Market-Entry Trends & Success Factors
• Total Benchmark Class Launch Data & Analysis

This new report benchmarks investment levels at each launch stage as well as budget and staffing allocation across critical medical and commercial activities for various market-entry situations or market-entry archetypes: portfolios featuring multiple molecules which treat single or multiple indications, and portfolios using single molecules to treat individual cancer types.

Download a complimentary report summary at: http://www.best-in-class.com/rr1482.htm.

ABOUT BEST PRACTICES, LLC
Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations.

View original content:http://www.prnewswire.com/news-releases/oncology-launch-study-probes-how-to-leverage-cost-savings-from-initial-launch-to-second-indication-launch-300589071.html

SOURCE Best Practices, LLC